Scholars Central

Research articlePublished 13 Sep 2013

Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population

Authors: Mackenzie Cottrell, R Chris Rathbun, Ryan Webb, Pete Johnson, Staci M Lockhart

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Morbidity and mortality rates from chronic liver disease secondary to hepatitis C virus (HCV) have become a significant issue for HIV infected patients. U.S. Department of Health and Human Service guidelines recommend HCV treatment for all coinfected patients without decompensated liver disease. Telaprevir and boceprevir are direct-acting agents (DAAs) recently approved for HCV genotype-1 mono-infection and have demonstrated marked improvements in viral suppression when combined with peg-interferon/ribavirin as triple therapy. Identification of co-infected patients who could benefit from HCV treatment is a necessary component of quality HIV care.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Virology & Antiviral Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Virology & Antiviral Research
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Mackenzie Cottrell”
  • BylineArticles whose byline prints “R Chris Rathbun”
  • BylineArticles whose byline prints “Ryan Webb”
  • BylineArticles whose byline prints “Pete Johnson”
  • BylineArticles whose byline prints “Staci M Lockhart”